Seres Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2013 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Seres Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2013 to 2024.
  • Seres Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2025 was -$24.9M, a 13.8% increase year-over-year.
  • Seres Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2025 was -$110M, a 53.6% increase year-over-year.
  • Seres Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$121M, a 37.8% increase from 2023.
  • Seres Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$195M, a 8.44% decline from 2022.
  • Seres Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$180M, a 179% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$121M +$73.8M +37.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 -$195M -$15.2M -8.44% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 -$180M -$115M -179% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-13
2021 -$64.5M +$23.6M +26.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-05
2020 -$88.1M -$16.3M -22.6% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-07
2019 -$71.9M +$28.4M +28.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$100M -$8.89M -9.73% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-02
2017 -$91.4M +$1.44M +1.56% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 -$92.8M -$38M -69.2% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-06
2015 -$54.9M -$39.8M -264% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$15.1M -$9.03M -149% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-16
2013 -$6.05M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.